共 97 条
Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: international consensus statement
被引:144
作者:
Sheean, G.
[1
]
Lannin, N. A.
[2
]
Turner-Stokes, L.
[3
]
Rawicki, B.
[4
]
Snow, B. J.
[5
]
机构:
[1] Univ Calif San Diego, San Diego, CA 92103 USA
[2] Univ Sydney, Sydney Med Sch, Rehabil Studies Unit, Ryde, NSW, Australia
[3] Kings Coll London, Sch Med, Harrow, Middx, England
[4] Monash Med Ctr, Victorian Paediat Rehabil Serv, Clayton, Vic 3168, Australia
[5] Auckland City Hosp, Dept Neurol, Auckland, New Zealand
关键词:
brain injury;
consensus statement;
spasticity;
stroke;
systematic review;
upper extremity;
RANDOMIZED CONTROLLED-TRIAL;
SPASTICITY FOLLOWING STROKE;
UPPER-EXTREMITY SPASTICITY;
HEMIPLEGIC SHOULDER PAIN;
INDUCED MOVEMENT THERAPY;
MOTOR-ASSESSMENT SCALE;
QUALITY-OF-LIFE;
DOUBLE-BLIND;
ELECTRICAL-STIMULATION;
POSTSTROKE SPASTICITY;
D O I:
10.1111/j.1468-1331.2010.03129.x
中图分类号:
R74 [神经病学与精神病学];
学科分类号:
摘要:
Upper limb spasticity affecting elbow, wrist, and finger flexors can be safely and effectively reduced with injections of botulinum toxin type-A (BoNT-A). It has been best studied in adults in the context of post-stroke spasticity. The clinical benefits include reduction in pain and deformity, improvement in washing and dressing the upper limb, and a reduction in caregiver burden (Class I evidence, recommendation level A). Some patients show improvement in function performed by active movement of the affected upper limb (Class III evidence, recommendation C), but predicting and measuring this is difficult, and further research is needed. An individually based approach to treatment and outcome measurement is preferred (Class IV, recommendation U). More research is needed to resolve many unknown issues of assessment and treatment, using research methods appropriate to the question.
引用
收藏
页码:74 / 93
页数:20
相关论文